These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 8972476)

  • 1. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
    Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
    Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
    Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
    Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
    Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
    Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas.
    Santin AD; Diamandis EP; Bellone S; Marizzoni M; Bandiera E; Palmieri M; Papasakelariou C; Katsaros D; Burnett A; Pecorelli S
    Am J Obstet Gynecol; 2006 May; 194(5):1296-302. PubMed ID: 16647913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis and the expression of Bcl-2 and Bax in patients with endometrioid, clear cell, and serous carcinomas of the uterine endometrium.
    Kokawa K; Shikone T; Otani T; Nishiyama R; Ishii Y; Yagi S; Yamoto M
    Gynecol Oncol; 2001 May; 81(2):178-83. PubMed ID: 11330946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
    Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
    Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
    Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
    Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hysteroscopic and immunohistochemical findings in type I and type II endometrial carcinomas.
    Maia H; Maltez A; Fahel P; Coutinho E
    J Am Assoc Gynecol Laparosc; 2001 May; 8(2):222-30. PubMed ID: 11342729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.
    Soslow RA; Shen PU; Chung MH; Isacson C
    Int J Gynecol Pathol; 1998 Apr; 17(2):129-34. PubMed ID: 9553809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
    Kallakury BV; Ambros RA; Hayner-Buchan AM; Sheehan CE; Malfetano JH; Ross JS
    Int J Gynecol Pathol; 1998 Oct; 17(4):320-6. PubMed ID: 9785132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features.
    Zheng W; Liang SX; Yu H; Rutherford T; Chambers SK; Schwartz PE
    Int J Surg Pathol; 2004 Jul; 12(3):207-23. PubMed ID: 15306933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
    Li C; Zota V; Woda BA; Rock KL; Fraire AE; Jiang Z; Lu D; Xu B; Dresser K; Lutman CV; Fischer AH
    Mod Pathol; 2007 Dec; 20(12):1263-8. PubMed ID: 17885673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
    McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
    Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
    Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
    J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.